Subscribe
Dapagliflozin is renoprotective and cardioprotective in chronic kidney disease patients, suggests a secondary analysis of the DAPA-CKD trial presented at Kidney Week 2020.
Finerenone Slows Renal Decline, Improves CV Outcomes in FIDELIO-DKD
Empagliflozin Receives FDA Fast Track Designation for Treatment of Kidney Disease
Heart Failure, Other CVD Increase Risk for ESRD
Hypertension in Dialysis Patients: Primary Care Primer
Girish Kunapareddy, MD; Sara M. Tolaney, MD, MPH
Yan Ji, MD; Neil M. Iyengar, MD
2 Sessions are Available!
2-Part Webinar Series
June 15, 2026
Seth A. Wander, MD, PhD; Ruta D. Rao, MD
Marla D. Lipsyc-Sharf, MD; Richard Zelkowitz, MD
Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO
June 17-19, 2026